MARÍA JOSÉ
SÁNCHEZ PÉREZ
DOCENTE INVITADA
Pfizer (United States)
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Pfizer (United States) (23)
2022
-
Barriers and Solutions to Improve Therapeutic Adherence from the Perspective of Primary Care and Hospital-Based Physicians
Patient Preference and Adherence, Vol. 16, pp. 697-707
2019
-
Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 19, Núm. 1, pp. 45-57
2018
-
Clinical and economic consequences of treating patients with peripheral neuropathic pain with brand name or generic drugs in routine clinical practice: The effects of age and sex
Neurologia, Vol. 33, Núm. 3, pp. 141-153
-
Cost of treating peripheral neuropathic pain with pregabalin or gabapentin at therapeutic doses in routine practice
Journal of Comparative Effectiveness Research, Vol. 7, Núm. 7, pp. 615-625
2017
-
Cost of treatment of peripheral neuropathic pain with pregabalin or gabapentin in routine clinical practice: impact of their loss of exclusivity
Journal of Evaluation in Clinical Practice, Vol. 23, Núm. 2, pp. 402-412
2015
-
Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice
Drug Design, Development and Therapy, Vol. 9, pp. 4329-4340
2014
-
Add-On Treatment with Pregabalin for Patients with Uncontrolled Neuropathic Pain Who Have Been Referred to Pain Clinics
Clinical Drug Investigation, Vol. 34, Núm. 12, pp. 833-844
-
Clinical characteristics, patient-reported outcomes, and previous therapeutic management of patients with uncontrolled neuropathic pain referred to pain clinics
Pain Research and Treatment, Vol. 2014
-
Erratum to: Effectiveness of pregabalin as monotherapy or combination therapy for neuropathic pain in patients unresponsive to previous treatments in a Spanish primary care setting (Clinical Drug Investigation (2013) 33, (633-645) DOI: 10.1007/s40261-013-0116-7)
Clinical Drug Investigation
-
Fe de errores de «Prevalencia del dolor neuropático (DN), según DN4, en atención primaria»
Semergen
2013
-
Clinical and resource utilization patterns in patients with refractory neuropathic pain prescribed pregabalin for the first time in routine medical practice in primary care settings in Spain
Pain Medicine (United States), Vol. 14, Núm. 12, pp. 1954-1963
-
Effectiveness of pregabalin as monotherapy or combination therapy for neuropathic pain in patients unresponsive to previous treatments in a Spanish primary care setting
Clinical Drug Investigation, Vol. 33, Núm. 9, pp. 633-645
2012
-
Broadening of generalized anxiety disorders definition does not affect the response to psychiatric care: Findings from the observational ADAN study
Clinical Practice and Epidemiology in Mental Health, Vol. 8, pp. 158-168
-
Cultural adaptation and validation of the painDETECT scale into Spanish
Clinical Journal of Pain, Vol. 28, Núm. 3, pp. 243-253
-
Pain related factors in newly diagnosed generalized anxiety disorder patients
Actas Espanolas de Psiquiatria, Vol. 40, Núm. 4, pp. 177-186
-
Pregabalin for the discontinuation of long-term benzodiazepines use: An assessment of its effectiveness in daily clinical practice
European Psychiatry, Vol. 27, Núm. 4, pp. 301-307
-
Prevalence and clinical features of newly diagnosed generalized anxiety disorder patients in Spanish primary care settings: The GADAP study
Actas Espanolas de Psiquiatria, Vol. 40, Núm. 3, pp. 105-113
2011
-
Effect of pregabalin in the treatment of refractory neck pain: Cost and clinical evidence from medical practice in orthopedic surgery and rehabilitation clinics
Pain Practice, Vol. 11, Núm. 4, pp. 369-380
-
Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use
European Addiction Research, Vol. 17, Núm. 5, pp. 262-270
-
Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: Better pain relief, sleep and physical health
Clinical and Translational Oncology, Vol. 13, Núm. 9, pp. 656-663